TransThera sets out Phase II tinengotinib data in The Lancet

Chinese biotech TransThera has reported new Phase II data showing its experimental kinase inhibitor tinengotinib delivered durable responses in patients with cholangiocarcinoma who had progressed after earlier FGFR-targeted therapies.

The findings, published in The Lancet Gastroenterology and Hepatology, highlight rising interest in next-generation agents for a rare but challenging cancer. Lead author Dr Milind Javle said tinengotinib “demonstrated durable responses and meaningful clinical benefit,” adding that results support a Phase III registration trial.

Tinengotinib, designed to block FGFR and compensatory resistance pathways, sits in a growing field shaped by Pemazyre (pemigatinib) and Lytgobi (futibatinib), which are widely used but limited by modest durability and frequent resistance. Analysts expect strong demand for new approaches as FGFR-driven cancers expand as a therapeutic category.